Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

219P - Clinical outcomes for advanced thymoma patients receiving platinum-based chemotherapy as first-line treatment


31 Mar 2023


Poster Display session


Yue Hao


Journal of Hepatology (2023) 18 (4S): S154-S159.


Y. Hao1, W. Sun2, X. Zeng2, Z. Shi2, W. Wang3, C. Xu4, Z. Song2

Author affiliations

  • 1 Hangzhou/CN
  • 2 zhejiang cancer hospital, hangzhou/CN
  • 3 Zhejiang Cancer Hospital, Hangzhou/CN
  • 4 Nanjing University School of Medicine, jinling/CN


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 219P


The rate of incidence for advanced thymoma is low. Reports on the promising efficacy and low toxicity of platinum-based chemotherapy in advanced thymoma are lacking. In addition, correlation for chemotherapy efficacy and safety among different subtypes of thymoma remains unexplored.


We analyzed the efficacy and safety of platinum-based chemotherapy as the first-line treatment for different types of thymoma patients. The objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and treatment-related adverse event results were obtained. Cox proportional hazards regression was analyzed to determine the factors independently associated with PFS.


The study evaluated 71 thymoma patients treated at the Zhejiang Cancer Hospital between January 2009 and March 2022. The ORR for advanced thymoma patients was 36.6%. PFS and OS for the whole cohort were 17.7 and 59.8 months, respectively. The difference in PFS between A-B2 (including A, AB, B1, and B2 subtypes) and B3 thymoma patients was significant (28.2 vs. 10.7 months, P = 0.015). Cox analysis results indicated that thymoma patient subtype was the only factor influencing the PFS.


Advanced thymoma patients can benefit from platinum-based chemotherapy. B3 thymoma patients demonstrated inferior efficacy of platinum-based chemotherapy used as the first-line treatment compared to A-B2 patients.

Legal entity responsible for the study

The authors.


Foundation of CSCO-Shiyao (Y-SY201901-0068, to Zhengbo Song).


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.